Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis

Cell Reports

Volumn 13, Issue 11, 2015, Pages 2553-2564

  Jin, Jing ^a,b   Liss, Nathan M ^a,b   Chen, Dong Hua ^c   Liao, Maofu ^d   Fox, Julie M ^e   Shimak, Raeann M ^e   Fong, Rachel H ^f   Chafets, Daniel ^a,b   Bakkour, Sonia ^a,b   Keating, Sheila ^a,b   Fomin, Marina E ^a,b   Muench, Marcus O ^a,b   Sherman, Michael B ^g   Doranz, Benjamin J ^f   Diamond, Michael S ^e   Simmons, Graham ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Integral Molecular Inc   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C9 ANTIBODY; CHK 152 ANTIBODY; CHK 166 ANTIBODY; CHK 9 ANTIBODY; CHK 95 ANTIBODY; CKV065 ANTIBODY; EPITOPE; GLUTAMIC ACID; GLYCINE; GLYCOPROTEIN E2; IM CKV063 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TRYPTOPHAN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; CHEMOKINE; CYTOKINE; VIRUS ENVELOPE PROTEIN;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY STRUCTURE; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; DRUG TARGETING; EPITOPE MAPPING; FEMALE; LIFE CYCLE; MEMBRANE FUSION; MOLECULAR INTERACTION; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE DRUG DOSE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS RELEASE; VIRUS SPIKE; ANIMAL; ARTHRITIS; C57BL MOUSE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR DYNAMICS; PATHOGENICITY; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; SITE DIRECTED MUTAGENESIS; VERO CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ARTHRITIS; CERCOPITHECUS AETHIOPS; CHEMOKINES; CHIKUNGUNYA VIRUS; CYTOKINES; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES; GENOTYPE; HUMANS; MEMBRANE FUSION; MICE; MICE, INBRED C57BL; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, QUATERNARY; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84952874591     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.11.043     Document Type: Article

References (42)

1. Akahata W., Yang Z.Y., Andersen H., Sun S., Holdaway H.A., Kong W.P., Lewis M.G., Higgs S., Rossmann M.G., Rao S., Nabel G.J. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 2010, 16:334-338.
2. Bernard E., Solignat M., Gay B., Chazal N., Higgs S., Devaux C., Briant L. Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS ONE 2010, 5:e11479.
3. Cheng R.H., Kuhn R.J., Olson N.H., Rossmann M.G., Choi H.K., Smith T.J., Baker T.S. Nucleocapsid and glycoprotein organization in an enveloped virus. Cell 1995, 80:621-630.
4. Corboba P., Grutadauria S., Cuffini C., Zapata M. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells. Viral Immunol. 2000, 13:83-92.
5. Couderc T., Lecuit M. Chikungunya virus pathogenesis: from bedside to bench. Antiviral Res. 2015, 121:120-131.
6. Couderc T., Chrétien F., Schilte C., Disson O., Brigitte M., Guivel-Benhassine F., Touret Y., Barau G., Cayet N., Schuffenecker I., et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008, 4:e29.
7. Díaz-Quiñonez J.A., Ortiz-Alcántara J., Fragoso-Fonseca D.E., Garcés-Ayala F., Escobar-Escamilla N., Vázquez-Pichardo M., Núñez-León A., Torres-Rodríguez Mde.L., Torres-Longoria B., López-Martínez I., et al. Complete genome sequences of chikungunya virus strains isolated in Mexico: first detection of imported and autochthonous cases. Genome Announc. 2015, 3. Published online May 7, 2015. 10.1128/genomeA.00300-15.
8. Dowdle W.R., Downie J.C., Laver W.G. Inhibition of virus release by antibodies to surface antigens of influenza viruses. J. Virol. 1974, 13:269-275.
9. Driscoll D.M., Onuma M., Olson C. Inhibition of bovine leukemia virus release by antiviral antibodies. Arch. Virol. 1977, 55:139-144.
10. Fischer M., Staples J.E. Notes from the field: chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014. MMWR Morb. Mortal. Wkly. Rep. 2014, 63:500-501. Arboviral Diseases Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC.
11. Fong R.H., Banik S.S., Mattia K., Barnes T., Tucker D., Liss N., Lu K., Selvarajah S., Srinivasan S., Mabila M., et al. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J. Virol. 2014, 88:14364-14379.
12. Forsell K., Xing L., Kozlovska T., Cheng R.H., Garoff H. Membrane proteins organize a symmetrical virus. EMBO J. 2000, 19:5081-5091.
13. Fric J., Bertin-Maghit S., Wang C.I., Nardin A., Warter L. Use of human monoclonal antibodies to treat Chikungunya virus infection. J. Infect. Dis. 2013, 207:319-322.
14. Garoff H., Sjöberg M., Cheng R.H. Budding of alphaviruses. Virus Res. 2004, 106:103-116.
15. Gibbons D.L., Vaney M.C., Roussel A., Vigouroux A., Reilly B., Lepault J., Kielian M., Rey F.A. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature 2004, 427:320-325.
16. Goh L.Y., Hobson-Peters J., Prow N.A., Gardner J., Bielefeldt-Ohmann H., Pyke A.T., Suhrbier A., Hall R.A. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin. Immunol. 2013, 149:487-497.
17. Hawman D.W., Stoermer K.A., Montgomery S.A., Pal P., Oko L., Diamond M.S., Morrison T.E. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J. Virol. 2013, 87:13878-13888.
18. Kajihara M., Marzi A., Nakayama E., Noda T., Kuroda M., Manzoor R., Matsuno K., Feldmann H., Yoshida R., Kawaoka Y., Takada A. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 2012, 86:13467-13474.
19. Kam Y.W., Lee W.W., Simarmata D., Harjanto S., Teng T.S., Tolou H., Chow A., Lin R.T., Leo Y.S., Rénia L., Ng L.F. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J. Virol. 2012, 86:13005-13015.
20. Kam Y.W., Lum F.M., Teo T.H., Lee W.W., Simarmata D., Harjanto S., Chua C.L., Chan Y.F., Wee J.K., Chow A., et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 2012, 4:330-343.
21. Kam Y.W., Simarmata D., Chow A., Her Z., Teng T.S., Ong E.K., Rénia L., Leo Y.S., Ng L.F. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 2012, 205:1147-1154.
22. Kaufmann B., Vogt M.R., Goudsmit J., Holdaway H.A., Aksyuk A.A., Chipman P.R., Kuhn R.J., Diamond M.S., Rossmann M.G. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. USA 2010, 107:18950-18955.
23. Lanciotti R.S., Valadere A.M. Transcontinental movement of Asian genotype chikungunya virus. Emerg. Infect. Dis. 2014, 20:1400-1402.
24. Lescar J., Roussel A., Wien M.W., Navaza J., Fuller S.D., Wengler G., Wengler G., Rey F.A. The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 2001, 105:137-148.
25. Li L., Jose J., Xiang Y., Kuhn R.J., Rossmann M.G. Structural changes of envelope proteins during alphavirus fusion. Nature 2010, 468:705-708.
26. Lum F.M., Teo T.H., Lee W.W., Kam Y.W., Rénia L., Ng L.F. An essential role of antibodies in the control of Chikungunya virus infection. J. Immunol. 2013, 190:6295-6302.
27. Masrinoul P., Puiprom O., Tanaka A., Kuwahara M., Chaichana P., Ikuta K., Ramasoota P., Okabayashi T. Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release. Virology 2014, 464-465:111-117.
28. Morrison T.E., Oko L., Montgomery S.A., Whitmore A.C., Lotstein A.R., Gunn B.M., Elmore S.A., Heise M.T. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 2011, 178:32-40.
29. Pal P., Dowd K.A., Brien J.D., Edeling M.A., Gorlatov S., Johnson S., Lee I., Akahata W., Nabel G.J., Richter M.K., et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013, 9:e1003312.
30. Schuffenecker I., Iteman I., Michault A., Murri S., Frangeul L., Vaney M.C., Lavenir R., Pardigon N., Reynes J.M., Pettinelli F., et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 2006, 3:e263.
31. Selvarajah S., Sexton N.R., Kahle K.M., Fong R.H., Mattia K.A., Gardner J., Lu K., Liss N.M., Salvador B., Tucker D.F., et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl. Trop. Dis. 2013, 7:e2423.
32. Shariff D.M., Davies J., Desperbasques M., Billstrom M., Geerligs H.J., Welling G.W., Welling-Wester S., Buchan A., Skinner G.R. Immune inhibition of virus release from human and nonhuman cells by antibody to viral and host cell determinants. Intervirology 1991, 32:28-36.
33. Smith T.J., Cheng R.H., Olson N.H., Peterson P., Chase E., Kuhn R.J., Baker T.S. Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc. Natl. Acad. Sci. USA 1995, 92:10648-10652.
34. Smith S.A., Silva L.A., Fox J.M., Flyak A.I., Kose N., Sapparapu G., Khomadiak S., Ashbrook A.W., Kahle K.M., Fong R.H., et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe 2015, 18:86-95.
35. Soonsawad P., Xing L., Milla E., Espinoza J.M., Kawano M., Marko M., Hsieh C., Furukawa H., Kawasaki M., Weerachatyanukul W., et al. Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding. J. Virol. 2010, 84:11145-11151.
36. Sun S., Xiang Y., Akahata W., Holdaway H., Pal P., Zhang X., Diamond M.S., Nabel G.J., Rossmann M.G. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. eLife 2013, 2:e00435.
37. Teng T.S., Kam Y.W., Lee B., Hapuarachchi H.C., Wimal A., Ng L.C., Ng L.F. A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection. J. Infect. Dis. 2015, 211:1925-1935.
38. Vanderplasschen A., Hollinshead M., Smith G.L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 1997, 78:2041-2048.
39. Voss J.E., Vaney M.C., Duquerroy S., Vonrhein C., Girard-Blanc C., Crublet E., Thompson A., Bricogne G., Rey F.A. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 2010, 468:709-712.
40. Watson R. Europe witnesses first local transmission of chikungunya fever in Italy. BMJ 2007, 335:532-533.
41. Xiao C., Rossmann M.G. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 2007, 158:182-187.
42. Zinkernagel R.M., LaMarre A., Ciurea A., Hunziker L., Ochsenbein A.F., McCoy K.D., Fehr T., Bachmann M.F., Kalinke U., Hengartner H. Neutralizing antiviral antibody responses. Adv. Immunol. 2001, 79:1-53.